PARP inhibitor
- Single-strand DNA breaks go unrepaired
- In BRCA/homologous-recombination-deficient tumors the double hit is lethal — synthetic lethality
- Normal cells with intact repair survive — the selectivity principle
- Myelosuppression
- Synthetic lethality in BRCA-mutated cancers
- Myelosuppression
Drugs with this mechanism (3)
- Niraparib — Oral PARP inhibitor for ovarian-cancer maintenance; thrombocytopenia drives individualized dosing.
- Olaparib — PARP inhibitor exploiting synthetic lethality in BRCA-mutated tumors.
- Rucaparib — PARP inhibitor for selected BRCA-mutated cancers; anemia, liver-enzyme elevations, and rare MDS/AML require monitoring.
All mechanisms · Open PARP inhibitor in the interactive console ↗